BlossomHill raises $100M in bid to repeat founders' cancer success at Turning Point
29 Feb 2024
Executive ChangeAcquisition
BlossomHill Therapeutics has closed a $100 million Series B to bring three of its oncology small molecules into the clinic and collect early efficacy data around the second half of 2025.
The San Diego biotech was created in 2020 by CEO J. Jean Cui and executive chair Y. Peter Li, the co-founders behind Turning Point Therapeutics. Cui had served as chief scientific officer at Turning Point, having been the lead inventor on its recently approved lung cancer drug Augtyro. She left in mid-2020, prior to its $4.1 billion sale to Bristol Myers Squibb in 2022.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.